Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 534 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR April is Occupational Therapy (OT) Month- What is OT and how... April 8, 2021 How to Strengthen Your Immune System: Part 1 September 17, 2020 Brentuximab May Mean Less Radiation for Children, Teens with Hodgkin Lymphoma May 7, 2021 Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a... April 23, 2024 Load more HOT NEWS More Than 25 Additional Years Needed to Slow an Increasing Incidence... FDA Approves Omidubicel to Reduce Time to Neutrophil Recovery and Infection... EMA Adopts a Positive Opinion for Biosimilar Denosumab New obesity strategy is a ‘landmark day for the nation’s health’...
